BACKGROUND: Indonesia has had the most human cases of highly pathogenic avian influenza A (H5N1) and one of the highest case-fatality rates worldwide. We described the factors associated with H5N1 case-fatality in Indonesia. METHODS: Between June, 2005, and February, 2008, there were 127 confirmed H5N1 infections. Investigation teams were deployed to investigate and manage each confirmed case; they obtained epidemiological and clinical data from case-investigation reports when possible and through interviews with patients, family members, and key individuals. FINDINGS: Of the 127 patients with confirmed H5N1 infections, 103 (81%) died. Median time to hospitalisation was 6 days (range 1-16). Of the 122 hospitalised patients for whom data were available, 121 (99%) had fever, 107 (88%) cough, and 103 (84%) dyspnoea on reaching hospital. However, for the first 2 days after onset, most had non-specific symptoms; only 31 had both fever and cough, and nine had fever and dyspnoea. Median time from onset to oseltamivir treatment was 7 days (range 0-21 days); treatment started within 2 days for one patient who survived, four (36.4%) of 11 receiving treatment within 2-4 days survived, six (37.5%) of 16 receiving treatment within 5-6 days survived, and ten (18.5%) of 44 receiving treatment at 7 days or later survived (p=0.03). Initiation of treatment within 2 days was associated with significantly lower mortality than was initiation at 5-6 days or later than 7 days (p<0.0001). Mortality was lower in clustered than unclustered cases (odds ratio 33.3, 95% CI 3.13-273). Treatment started at a median of 5 days (range 0-13 days) from onset in secondary cases in clusters compared with 8 days (range 4-16) for primary cases (p=0.04). INTERPRETATION: Development of better diagnostic methods and improved case management might improve identification of patients with H5N1 influenza, which could decrease mortality by allowing for earlier treatment with oseltamivir.
BACKGROUND: Indonesia has had the most human cases of highly pathogenic avian influenza A (H5N1) and one of the highest case-fatality rates worldwide. We described the factors associated with H5N1 case-fatality in Indonesia. METHODS: Between June, 2005, and February, 2008, there were 127 confirmed H5N1 infections. Investigation teams were deployed to investigate and manage each confirmed case; they obtained epidemiological and clinical data from case-investigation reports when possible and through interviews with patients, family members, and key individuals. FINDINGS: Of the 127 patients with confirmed H5N1 infections, 103 (81%) died. Median time to hospitalisation was 6 days (range 1-16). Of the 122 hospitalised patients for whom data were available, 121 (99%) had fever, 107 (88%) cough, and 103 (84%) dyspnoea on reaching hospital. However, for the first 2 days after onset, most had non-specific symptoms; only 31 had both fever and cough, and nine had fever and dyspnoea. Median time from onset to oseltamivir treatment was 7 days (range 0-21 days); treatment started within 2 days for one patient who survived, four (36.4%) of 11 receiving treatment within 2-4 days survived, six (37.5%) of 16 receiving treatment within 5-6 days survived, and ten (18.5%) of 44 receiving treatment at 7 days or later survived (p=0.03). Initiation of treatment within 2 days was associated with significantly lower mortality than was initiation at 5-6 days or later than 7 days (p<0.0001). Mortality was lower in clustered than unclustered cases (odds ratio 33.3, 95% CI 3.13-273). Treatment started at a median of 5 days (range 0-13 days) from onset in secondary cases in clusters compared with 8 days (range 4-16) for primary cases (p=0.04). INTERPRETATION: Development of better diagnostic methods and improved case management might improve identification of patients with H5N1 influenza, which could decrease mortality by allowing for earlier treatment with oseltamivir.
Authors: Benjamin J Cowling; Lianmei Jin; Eric H Y Lau; Qiaohong Liao; Peng Wu; Hui Jiang; Tim K Tsang; Jiandong Zheng; Vicky J Fang; Zhaorui Chang; Michael Y Ni; Qian Zhang; Dennis K M Ip; Jianxing Yu; Yu Li; Liping Wang; Wenxiao Tu; Ling Meng; Joseph T Wu; Huiming Luo; Qun Li; Yuelong Shu; Zhongjie Li; Zijian Feng; Weizhong Yang; Yu Wang; Gabriel M Leung; Hongjie Yu Journal: Lancet Date: 2013-06-24 Impact factor: 79.321
Authors: Jonathan Hsu; Nancy Santesso; Reem Mustafa; Jan Brozek; Yao Long Chen; Jessica P Hopkins; Adrienne Cheung; Gayane Hovhannisyan; Liudmila Ivanova; Signe A Flottorp; Ingvil Saeterdal; Arthur D Wong; Jinhui Tian; Timothy M Uyeki; Elie A Akl; Pablo Alonso-Coello; Fiona Smaill; Holger J Schünemann Journal: Ann Intern Med Date: 2012-02-27 Impact factor: 25.391
Authors: Maria E Lorenzo; Andrea Hodgson; Dionne P Robinson; Jenifer B Kaplan; Andrew Pekosz; Sabra L Klein Journal: Vaccine Date: 2011-10-06 Impact factor: 3.641
Authors: Shawn Babiuk; Randy Albrecht; Yohannes Berhane; Peter Marszal; Jürgen A Richt; Adolfo García-Sastre; John Pasick; Hana Weingartl Journal: J Gen Virol Date: 2009-11-04 Impact factor: 3.891
Authors: Michael C W Chan; Denise I T Kuok; Connie Y H Leung; Kenrie P Y Hui; Sophie A Valkenburg; Eric H Y Lau; John M Nicholls; Xiaohui Fang; Yi Guan; Jae W Lee; Renee W Y Chan; Robert G Webster; Michael A Matthay; J S Malik Peiris Journal: Proc Natl Acad Sci U S A Date: 2016-03-14 Impact factor: 11.205
Authors: Jack T Nguyen; Justin D Hoopes; Donald F Smee; Mark N Prichard; Elizabeth M Driebe; David M Engelthaler; Minh H Le; Paul S Keim; R Paul Spence; Gregory T Went Journal: Antimicrob Agents Chemother Date: 2009-07-20 Impact factor: 5.191
Authors: Robert H E Friesen; Wouter Koudstaal; Martin H Koldijk; Gerrit Jan Weverling; Just P J Brakenhoff; Peter J Lenting; Koert J Stittelaar; Albert D M E Osterhaus; Ronald Kompier; Jaap Goudsmit Journal: PLoS One Date: 2010-02-08 Impact factor: 3.240